Surfing the NASH Tsunami

Day Three of TLMdX 2020 - Sunday at The Digital Liver Meeting -- The Future Looks Bright! - Ep 36

November 16, 2020 HEP Dynamics LLC Season 1 Episode 36
Surfing the NASH Tsunami
Day Three of TLMdX 2020 - Sunday at The Digital Liver Meeting -- The Future Looks Bright! - Ep 36
Chapters
Surfing the NASH Tsunami
Day Three of TLMdX 2020 - Sunday at The Digital Liver Meeting -- The Future Looks Bright! - Ep 36
Nov 16, 2020 Season 1 Episode 36
HEP Dynamics LLC

Reviews of Phase 2 drug trials and diagnostic strategies reveal that NASH is close to multiple breakthroughs.

Naim Alkhouri and Mazen Noureddin join Louise and Roger to review highlights from Sunday at The Digital Liver Meeting. Naim, Mazen and Roger review results from drug trials that reveal that multiple drugs (monotherapies and combinations) with potent effects on liver fat reduction and fibrosis are moving through the pipeline. Louise discusses a trial that relies on non-invasive techniques to assess histologic improvement and fibrosis regression in cirrhotic patients, signaling one more way that non-invasive techniques might replace biopsy. Finally, Louise and Roger team up to discuss a US-based 20-year study showing us the many ways that lean NASH prognosis and co-morbidities differ from overweight or obese NASH. A session filled with information, theorizing and high spirits!

Show Notes

Reviews of Phase 2 drug trials and diagnostic strategies reveal that NASH is close to multiple breakthroughs.

Naim Alkhouri and Mazen Noureddin join Louise and Roger to review highlights from Sunday at The Digital Liver Meeting. Naim, Mazen and Roger review results from drug trials that reveal that multiple drugs (monotherapies and combinations) with potent effects on liver fat reduction and fibrosis are moving through the pipeline. Louise discusses a trial that relies on non-invasive techniques to assess histologic improvement and fibrosis regression in cirrhotic patients, signaling one more way that non-invasive techniques might replace biopsy. Finally, Louise and Roger team up to discuss a US-based 20-year study showing us the many ways that lean NASH prognosis and co-morbidities differ from overweight or obese NASH. A session filled with information, theorizing and high spirits!